|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:VEGF_Trap-Eye_Study
|
|
gptkbp:activities
|
VEGF inhibition
inhibits vascular endothelial growth factor (VEGF)
|
|
gptkbp:appointed_by
|
injection
ophthalmology
intravitreal injection
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:FDA
gptkb:United_States
|
|
gptkbp:clinical_trial
|
gptkb:psychologist
Phase III
Phase III trials
retinal vein occlusion
choroidal neovascularization
diabetic macular edema
wet age-related macular degeneration
|
|
gptkbp:developed_by
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:formulation
|
solution for injection
intravitreal injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VEGF Trap-Eye
|
|
gptkbp:indication
|
gptkb:myopic_choroidal_neovascularization
retinal vein occlusion
diabetic macular edema
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_compared_to
|
gptkb:ranibizumab
|
|
gptkbp:is_similar_to
|
gptkb:ranibizumab
|
|
gptkbp:is_used_for
|
treatment of retinal diseases
treatment of eye diseases
|
|
gptkbp:marketed_as
|
gptkb:Eylea
|
|
gptkbp:side_effect
|
retinal detachment
cataract
intraocular inflammation
cataract formation
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor_(VEGF)
|